LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Thera… Read more
LENZ Therapeutics Inc (LENZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.044x
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has a cash flow conversion efficiency ratio of -0.044x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.59 Million) by net assets ($193.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LENZ Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how LENZ Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LENZ Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LENZ Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lumax International Corp Ltd
TW:6192
|
0.041x |
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
0.182x |
|
Jamna Auto Industries Limited
NSE:JAMNAAUTO
|
0.273x |
|
SK Discovery Co Ltd
KO:006125
|
0.001x |
|
Supermax Corporation Berhad
PINK:SPMXF
|
0.003x |
|
XP Power Limited
PINK:XPPLF
|
0.066x |
|
PONCE FIN. GROUP DL -01
F:73V0
|
N/A |
|
Piraeus Port Authority S.A
AT:PPA
|
0.158x |
Annual Cash Flow Conversion Efficiency for LENZ Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of LENZ Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $204.08 Million | $-59.39 Million | -0.291x | -144.68% |
| 2023-12-31 | $-92.71 Million | $-60.38 Million | 0.651x | -82.11% |
| 2022-12-31 | $-24.17 Million | $-87.98 Million | 3.640x | -2.10% |
| 2021-12-31 | $-14.21 Million | $-52.85 Million | 3.718x | +317.84% |
| 2020-12-31 | $-9.80 Million | $-8.72 Million | 0.890x | +10288.39% |
| 2019-12-31 | $-2.22 Million | $-19.00K | 0.009x | -- |